Exelixis, Inc.
Description
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
About
CEO
Dr. Michael M. Morrissey Ph.D.
Employees
1,310
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNGS
Address
1851 Harbor Bay Parkway, Alameda, CA 94502, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Oct 27, 2025 | — | — | — | — |
| Aug 4, 2025 | — | — | — | — |
| Apr 28, 2025 | — | — | — | — |
| Feb 12, 2025 | 0.39 | — | — | — |
| Feb 4, 2025 | 0.39 | — | — | — |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 7 | — | 13 |
| Average estimate | — | 0.41 | — | 2.15 |
| Low estimate | — | 0.26 | — | 1.78 |
| High estimate | — | 0.63 | — | 2.53 |
| Last year EPS | — | 0.17 | — | 1.94 |
[stock_revenue_estimate]
Growth estimates
Current qtr
46.750%
Next qtr. (Mar 2025)
142.020%
Current year
115.780%
Next year (Dec 2025)
10.880%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 1.83B | 1.61B | 1.43B | 987.54M | 967.78M |
| Cost of revenue | 72.55M | 57.91M | 52.87M | 36.27M | 33.10M |
| Gross profit | 1.76B | 1.55B | 1.38B | 951.27M | 934.68M |
| Operating expense | |||||
| Research & development | 1.04B | 891.81M | 693.72M | 547.85M | 336.96M |
| Selling general and admin | 542.71M | 459.86M | 401.72M | 293.36M | 228.24M |
| Other operating expenses | — | — | — | — | — |
| Operating income | 170.89M | 201.48M | 286.67M | 110.06M | 369.47M |
| Non operating interest income | |||||
| Income | 86.54M | 33.07M | 7.67M | 19.87M | 27.96M |
| Expense | — | — | — | — | — |
| Other income expense | 93,000 | -197,000 | -184,000 | 912,000 | 680,000 |
| Pretax income | 257.52M | 234.35M | 294.15M | 130.84M | 398.11M |
| Tax provision | 49.76M | 52.07M | 63.09M | 19.06M | 77.10M |
| Net income | 207.77M | 182.28M | 231.06M | 111.78M | 321.01M |
| Basic EPS | 0.65 | 0.56 | 0.73 | 0.36 | 1.06 |
| Diluted EPS | 0.65 | 0.56 | 0.72 | 0.35 | 1.02 |
| Basic average shares | 318.15M | 324.56M | 314.88M | 308.27M | 302.58M |
| Diluted average shares | 318.15M | 324.56M | 314.88M | 308.27M | 302.58M |
| EBITDA | 196.60M | 222.36M | 300.30M | 119.20M | 377.82M |
| Net income from continuing op. | 207.77M | 182.28M | 231.06M | 111.78M | 321.01M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 2.94B | 3.07B | 2.62B | 2.14B | 1.89B |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 262.99M | 501.20M | 647.17M | 319.22M | 266.50M |
| Other short term investments | 732.31M | 807.27M | 819.91M | 887.32M | 585.74M |
| Accounts receivable | 237.41M | 214.78M | 282.65M | 160.88M | 119.07M |
| Other receivables | — | — | — | — | — |
| Inventory | 17.32M | 33.30M | 27.49M | 20.97M | 12.89M |
| Prepaid assets | — | — | 57.53M | 57.01M | 26.99M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 67.93M | 62.21M | 57.53M | — | — |
| Non current assets | |||||
| Properties | 393.03M | 330.18M | 154.75M | 11.71M | 8.90M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 44.71M | 43.62M | 30.66M | 33.31M | 30.39M |
| Construction in progress | 24.47M | 4.93M | 16.87M | 16.36M | 1.25M |
| Leases | 89.04M | 83.33M | 73.59M | 40.69M | 33.90M |
| Accumulated depreciation | -80.39M | -60.87M | -40.83M | -34.68M | -25.56M |
| Goodwill | 127.37M | 127.37M | 127.37M | 127.37M | 127.37M |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | 728.72M | 756.73M | 371.11M | 330.75M | 536.39M |
| Other non current assets | 361.15M | 231.11M | 242.67M | 230.12M | 225.52M |
| Total liabilities | 678.45M | 583.06M | 405.62M | 258.22M | 199.70M |
| Current liabilities | |||||
| Accounts payable | 33.77M | 32.67M | 24.26M | 23.63M | 11.58M |
| Accrued expenses | 99.15M | 85.26M | 164.30M | 64.71M | 50.63M |
| Short term debt | — | — | — | — | 2.73M |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | 93.33M | 77.16M | 61.97M | 51.19M | 37.36M |
| Other current liabilities | 108.42M | 78.92M | 53.37M | 44.45M | 24.45M |
| Non current liabilities | |||||
| Long term debt | 189.94M | 190.17M | 51.27M | 49.09M | 48.01M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 94.22M | 68.53M | 8.02M | 721,000 | 2.35M |
| Shareholders equity | |||||
| Common stock | 303,000 | 324,000 | 319,000 | 312,000 | 305,000 |
| Retained earnings | -173.35M | -34.23M | -216.51M | -447.57M | -559.35M |
| Other shareholders equity | -3.75M | -14.52M | -758,000 | 4.48M | 3.07M |
| Total shareholders equity | 2.26B | 2.49B | 2.21B | 1.88B | 1.69B |
| Additional paid in capital | 2.44B | 2.54B | 2.43B | 2.32B | 2.24B |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||||
| Net Income | 207.77M | 182.28M | 231.06M | 111.78M | 321.01M | 690.07M | 154.23M | -70.22M | -161.74M | -261.30M | -244.76M | -147.65M | 75.70M | -92.33M | -139.56M | -175.57M | -86.38M | -101.49M | -84.40M | -137.25M | -94.77M | -86.13M | -71.19M | -75.31M | -18.70M |
| Depreciation | 25.72M | 20.88M | 13.63M | 9.14M | 8.35M | 4.92M | 1.19M | 1.00M | 1.41M | 2.39M | 3.15M | 5.51M | 6.82M | 10.54M | 12.60M | 13.23M | 11.33M | 16.91M | 17.76M | 17.49M | 17.75M | 16.70M | 15.21M | 18.86M | 5.70M |
| Deferred Taxes | -133.21M | -60.36M | 46.53M | 15.27M | 71.00M | -244.11M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 106.35M | 107.57M | 119.82M | 105.07M | 56.60M | 40.63M | 23.94M | 23.95M | 21.98M | 10.01M | 12.03M | 8.83M | 12.10M | 21.11M | 22.91M | 22.91M | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | 140.68M | 125.04M | 28.78M | 7.87M | 2.91M | 3.98M | -6.80M | 17.00M | 22.72M | 26.45M | 33.08M | 18.79M | 13.29M | 10.16M | 1.62M | 946,000 | -4.47M | 18.37M | — | — | — | — | — | — | — |
| Accounts Receivable | -22.62M | 66.85M | -122.32M | -42.47M | 43.72M | -85.47M | -43.30M | -35.32M | -540,000 | -941,000 | -1.19M | 27.04M | -24.29M | 5.97M | -8.51M | 201,000 | 17.70M | -15.09M | -2.76M | 186,000 | -580,000 | 637,000 | -529,000 | -918,000 | -200,000 |
| Accounts Payable | 53.25M | 25.84M | 55.09M | 50.51M | 39.69M | 17.14M | 26.31M | 164,000 | -12,000 | -2.93M | 8.69M | 5.15M | -14.80M | -9.44M | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -16.12M | -14.17M | -2.20M | -22.95M | -15.03M | -2.30M | 26.05M | 274.97M | -35.17M | -10.81M | -10.80M | -39.06M | -236.34M | -38.79M | 86.91M | 127.70M | 8.38M | 46.13M | 33.47M | -1.67M | -8.12M | 33.56M | 13.22M | 6.25M | 2.80M |
| Operating Cash Flow | 361.80M | 453.94M | 370.38M | 234.21M | 528.24M | 424.85M | 181.62M | 211.55M | -151.37M | -237.13M | -199.81M | -121.38M | -167.53M | -92.79M | -24.04M | -10.59M | -53.45M | -35.18M | -35.93M | -121.23M | -85.73M | -35.23M | -43.29M | -51.12M | -10.40M |
| Investing Activities | |||||||||||||||||||||||||
| Capital Expenditures | -40.47M | -27.71M | -54.23M | -30.35M | -12.83M | -32.99M | -20.98M | -1.61M | 899,000 | -82,000 | -2.03M | -774,000 | 535,000 | -1.65M | -5.91M | -15.21M | -17.40M | -11.60M | -14.17M | -12.34M | -14.25M | -5.85M | -266,000 | -5.31M | -5.00M |
| Net Intangibles | -122.50M | -110.75M | -10.00M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — | 2.49M | 95,000 | 838,000 | — | — | 3.01M | 9.00M | 2.20M | 9.00M | 35.31M | — | — | -1.60M | — | — | — | — | — |
| Purchase of Investments | -902.47M | -1.45B | -1.36B | -1.07B | -1.18B | -557.83M | -319.09M | -369.19M | -143.99M | -119.53M | -189.98M | -533.48M | -237.21M | -167.32M | -163.64M | -2.66M | -206.10M | -134.08M | -150.08M | -93.47M | -218.22M | -147.89M | -150.84M | -135.82M | -1.50M |
| Sale of Investments | 1.04B | 1.06B | 1.38B | 969.40M | 608.27M | 292.97M | 376.86M | 156.25M | 179.03M | 252.89M | 325.17M | 310.77M | 180.01M | 140.35M | 55.03M | 126.94M | 182.77M | 120.93M | 120.24M | 139.08M | 222.71M | 206.31M | 156.52M | 44.69M | — |
| Investing Cash Flow | 95.55M | -413.66M | -32.88M | -131.22M | -587.25M | -297.85M | 35.80M | -213.55M | 50.17M | 146.33M | 144.35M | -259.47M | -51.46M | -19.57M | -114.75M | 121.30M | -3.02M | -21.70M | -40.65M | 20.46M | -14.60M | 46.81M | 5.41M | -96.44M | -6.50M |
| Financing Activities | |||||||||||||||||||||||||
| Long-Term Debt Issuance | — | — | — | — | — | — | — | — | — | — | — | 277.67M | 2.59M | 165.01M | 5.00M | 13.62M | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | — | — | — | — | — | -13,000 | -185.79M | -7.71M | -4.38M | -11.71M | -13.17M | -4.87M | -8.62M | -39.56M | -43.07M | -17.45M | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | -29.12M | -23.30M | -39.11M | -50.02M | -9.95M | -7.59M | -6.56M | -4.11M | -534,000 | — | — | — | — | — | -25,000 | — | — | 40.00M | 37.00M | — | 733,000 | 995,000 | — | 297,000 | -100,000 |
| Financing Cash Flow | -579.50M | -23.30M | -39.11M | -50.02M | -9.95M | -7.60M | -192.35M | -11.82M | 140.73M | 63.93M | -13.17M | 476.28M | 173.34M | 125.45M | -34.26M | 320,000 | 83.76M | 136.54M | 99.44M | 5.06M | 77.57M | 7.83M | 12.93M | 126.23M | 8.80M |
| Other Cash Details | |||||||||||||||||||||||||
| End Cash Position | 262.99M | 502.68M | 663.89M | 320.77M | 268.14M | 315.88M | 188.31M | 155.84M | 141.63M | 80.40M | 103.98M | 170.07M | 74.26M | 97.44M | 86.80M | 247.70M | 135.46M | 123.37M | 81.33M | 78.11M | 111.83M | 90.28M | 35.58M | 19.55M | 5.40M |
| Income Tax Paid | 185.66M | 127.87M | 12.96M | 4.12M | 7.87M | 10.68M | 538,000 | 190,000 | 192,000 | 60,000 | — | 1.12M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | — | — | — | — | — | — | 20.46M | 21.04M | 19.82M | 19.11M | 19.16M | 6.98M | 6.84M | 11.06M | 10.53M | 355,000 | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 170.36M | 224.16M | 336.58M | 178.64M | 514.12M | 382.42M | 144.47M | 208.70M | -141.50M | -235.88M | -200.94M | -125.86M | -160.22M | -102.86M | -20.50M | -24.89M | -86.14M | -56.95M | -60.72M | -106.17M | -93.49M | -36.78M | -32.86M | -28.25M | -12.30M |
Error: Invalid format in Holders JSON file.
Article
2 Stocks to Buy With Less Than $40
Some think investing in stocks requires substantial start-up capital, but that's false. Even with a modest sum, like $40, investors can acquire shares of companies whose long-term prospects look exciting, and all for the price of a few breakfast items.
Feb 10, 2025
Article
EXEL or TECH: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Techne (TECH). But which of these two stocks is more attractive to value investors?
Feb 6, 2025
Article
4 PEG-Based GARP Stocks to Stay Ahead in Uncertain Markets
Here are four PEG-driven GARP stocks, PPC, EXEL, SYF and UAL, which qualify our screening criteria.
Feb 6, 2025
